ArticleClinical and diagnostic laboratory immunology2002
Immune responses to bile-tolerant helicobacter species in patients with chronic liver diseases, a randomized population group, and healthy blood donors.
Article in Clinical and diagnostic laboratory immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Role ofWorld journal of gastroenterology · 2025Article
- Helicobacter hepaticus augmentation triggers Dopaminergic degeneration and motor disorders in mice with Parkinson's disease.Molecular psychiatry · 2023Article
- Validation of Multiplex PCR and Serology DetectingMicroorganisms · 2023Article
- Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.Helicobacter · 2020Article
- Review
- Association between Helicobacter spp. infections and hepatobiliary malignancies: a review.World journal of gastroenterology · 2015Review
- Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice.Nature · 2012Article
- Detection of Helicobacter hepaticus in human bile samples of patients with biliary disease.Helicobacter · 2009Article
- Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract.British journal of cancer · 2009Article
- Cross-reactivity between immune responses to Helicobacter bilis and Helicobacter pylori in a population in Thailand at high risk of developing cholangiocarcinoma.Clinical and vaccine immunology : CVI · 2008Article
- Helicobacter pullorum in chickens, Belgium.Emerging infectious diseases · 2006Article
- Differential detection of five mouse-infecting helicobacter species by multiplex PCR.Clinical and diagnostic laboratory immunology · 2005Article
- Recombinant Helicobacter bilis protein P167 for mouse serodiagnosis in a multiplex microbead assay.Clinical and diagnostic laboratory immunology · 2004Article
- In vitro and in vivo characterization of Helicobacter hepaticus cytolethal distending toxin mutants.Infection and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bile-tolerant Helicobacter species such as Helicobacter pullorum, Helicobacter bilis, and Helicobacter hepaticus are associated with hepatic disorders in animals and may be involved in the pathogenesis of chronic liver diseases (CLD) in humans. Antibody responses to cell surface proteins of H. pullorum, H. bilis, and H. hepaticus in serum samples from patients with CLD, a randomized population group, and healthy blood donors were evaluated by using enzyme linked immunosorbent assay (ELISA). The results were compared with the antibody responses to Helicobacter pylori. For analysis of a possible cross-reactivity between bile-tolerant Helicobacter species and H. pylori, sera from a subpopulation of each group were absorbed with a whole-cell extract of H. pylori and retested by ELISA. Results before absorption showed that the mean value of the ELISA units for H. pullorum was significantly higher in patients with CLD than in healthy blood donors (P = 0.01). Antibody reactivity to cell surface protein of H. hepaticus was also significantly higher in the CLD patients than in the healthy blood donors and the population group (P = 0.005 and P = 0.002, respectively). Following the absorption, antibody responses to H. pullorum decreased significantly in all three groups (P = 0.0001 for CLD patients, P = 0.0005 for the population group, and P < 0.0001 for the blood donors), indicating that cross-reactivity between H. pylori and other Helicobacter spp. occurs. The antibody responses to H. hepaticus and H. bilis in CLD patients remained high following absorption experiments compared to ELISA results before absorption. The significance of this finding requires further investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.